Neurological toxicities associated with chimeric antigen receptor T-cell therapy.

Research paper by Daniel B DB Rubin, Husain H HH Danish, Ali Basil AB Ali, Karen K Li, Sarah S LaRose, Andrew D AD Monk, David J DJ Cote, Lauren L Spendley, Angela H AH Kim, Matthew S MS Robertson, Matthew M Torre, Timothy R TR Smith, Saef S Izzy, Caron A CA Jacobson, Jong Woo JW Lee, et al.

Indexed on: 01 May '19Published on: 21 Mar '19Published in: Brain : a journal of neurology


Chimeric antigen receptor T cell therapy has become an important tool in the treatment of relapsed and refractory malignancy; however, it is associated with significant neurological toxicity. We characterized the neurological toxicity associated with chimeric antigen receptor T-cell therapy in a consecutive series of 100 patients up to 2 months post transfusion, 28 of whom were obtained from chart review and the others by prospective observation. The underlying neoplasms were lymphoma (74%), myeloma (14%), leukaemia (10%), and sarcoma (2%). The median age of the cohort was 64.5 years old and 39% of patients were female. The most commonly occurring neurological symptoms were encephalopathy (57%), headache (42%), tremor (38%), aphasia (35%) and focal weakness (11%). Focal neurological deficits are frequently observed after chimeric antigen receptor T-cell therapy and are associated with regional EEG abnormalities, FDG-PET hypometabolism, and elevated velocities on transcranial Doppler ultrasound. In contrast, structural imaging was typically normal. As this form of treatment is more widely adopted, recognition of the frequently encountered symptoms will be of increasing importance for the neurologists and oncologists caring for this growing patient population. © The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.